Geode Capital Management LLC Raises Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 12.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,094,644 shares of the company’s stock after acquiring an additional 124,071 shares during the quarter. Geode Capital Management LLC’s holdings in Cabaletta Bio were worth $5,168,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Walleye Capital LLC boosted its position in shares of Cabaletta Bio by 111.6% during the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock worth $1,897,000 after purchasing an additional 212,025 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Cabaletta Bio during the third quarter worth $3,150,000. E Fund Management Co. Ltd. boosted its position in shares of Cabaletta Bio by 1,610.1% during the second quarter. E Fund Management Co. Ltd. now owns 286,424 shares of the company’s stock worth $2,142,000 after buying an additional 269,675 shares during the period. XTX Topco Ltd grew its stake in shares of Cabaletta Bio by 490.2% in the third quarter. XTX Topco Ltd now owns 87,455 shares of the company’s stock valued at $413,000 after buying an additional 72,638 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Cabaletta Bio by 70.7% in the 2nd quarter. Victory Capital Management Inc. now owns 634,217 shares of the company’s stock valued at $4,744,000 after buying an additional 262,594 shares during the period.

Cabaletta Bio Stock Performance

NASDAQ:CABA opened at $2.40 on Friday. Cabaletta Bio, Inc. has a 1 year low of $1.76 and a 1 year high of $26.35. The stock has a market cap of $117.30 million, a P/E ratio of -1.12 and a beta of 2.37. The stock has a 50-day simple moving average of $3.10 and a 200-day simple moving average of $4.80.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CABA shares. Evercore ISI cut Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their target price for the company from $15.00 to $6.00 in a report on Friday, December 20th. UBS Group initiated coverage on shares of Cabaletta Bio in a report on Thursday, October 10th. They issued a “buy” rating and a $10.00 price objective for the company. Wells Fargo & Company lowered shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $12.00 to $6.00 in a report on Thursday, December 19th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $24.38.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.